EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions

Faure Delgado Leon, Suset Almuinas de Armas, Melanie Molina, Eric G Morales, Maria Fernandez-Gomez iD, Luis Estuardo Raez iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Faure Delgado Leon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Oncogene Proteins, Fusion, Molecular Targeted Therapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Actionable ALK, ROS1, RET, NTRK, and NRG1 fusions define biologically distinct subsets of advanced non-small cell lung cancer (NSCLC), yet real-world data across these rare populations remain limited. We retrospectively evaluated patients with advanced NSCLC treated at Memorial Healthcare System who received genotype-matched fusion-directed therapy; the first fusion-directed agent defined the index treatment, and survival was measured from its initiation. Progression was determined from radiographic reports and treating-oncologist documentation. After patient-level reconciliation, 59 unique patients were included: 29 ALK, 14 ROS1, 11 RET, 3 NTRK, and 2 NRG1. Median follow-up was 47.7 months (95% CI, 28.6–58.7), median progression-free survival was 44.8 months (95% CI, 17.1–not estimable), and median overall survival was not reached. No statistically significant survival differences were detected among ALK, ROS1, and RET subgroups, although limited sample sizes preclude exclusion of clinically meaningful differences. Later-line index therapy was not significantly associated with progression-free survival in exploratory unadjusted analysis. These findings provide descriptive real-world evidence of precision-oncology implementation across actionable fusion-defined NSCLC while underscoring that pooled outcomes should not be interpreted as evidence of equivalent efficacy across molecular subtypes or therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOncogene Proteins, FusionMolecular Targeted TherapyGene FusionHumansFemaleMaleMiddle AgedAgedProtein-Tyrosine KinasesRetrospective StudiesProto-Oncogene Proteins c-retProto-Oncogene ProteinsAdultTreatment OutcomeAnaplastic Lymphoma Kinase

Stichwörter der Autor:innen

gene fusionnext-generation sequencingnon-small cell lung cancerprecision oncologyreal-world evidencetargeted therapy

Substanzen

Oncogene Proteins, FusionProtein-Tyrosine KinasesROS1 protein, humanProto-Oncogene Proteins c-retProto-Oncogene ProteinsAnaplastic Lymphoma KinaseALK protein, human

Autor:innen und Institutionen

  • Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA.
  • Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
  • Oncology Research Department, Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33026, USA.
  • Memorial Cancer Institute, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA.

ORCID-Profile: Maria Fernandez-Gomez, Luis Estuardo Raez

Zitieren

APA

Delgado Leon, F., de Armas, S. A., Molina, M., Morales, E. G., Fernandez-Gomez, M., & Raez, L. E. (2026). Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177849

Vancouver

Delgado Leon F, de Armas SA, Molina M, Morales EG, Fernandez-Gomez M, Raez LE. Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177849

BibTeX
@article{DelgadoLeon2026,
  author = {Delgado Leon, Faure and de Armas, Suset Almuinas and Molina, Melanie and Morales, Eric G and Fernandez-Gomez, Maria and Raez, Luis Estuardo},
  title = {Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177849}
}
Kostenlos starten →